Phenylurea Compounds Concept

subject area of

• A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186  Journal Articles
• A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: A trial of the Chicago, PMH, and California Phase II Consortia  Journal Articles
• A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer  Journal Articles
• A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer  Journal Articles
• A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium  Journal Articles
• A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study  Journal Articles
• Adult skin-derived precursor Schwann cells exhibit superior myelination and regeneration supportive properties compared to chronically denervated nerve-derived Schwann cells  Journal Articles
• BAY 43-9006: Early Clinical Data in Patients with Advanced Solid Malignancies  Journal Articles
• Changes in Liver Volume Observed Following Sorafenib and Liver Radiation Therapy  Journal Articles
• Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study  Journal Articles
• Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial  Journal Articles
• Development of Potent Forchlorfenuron Analogs and Their Cytotoxic Effect in Cancer Cell Lines.  Journal Articles
• Distribution of cholecystokinin receptors in the bovine brain: A quantitative autoradiographic study  Journal Articles
• Emesis induced by inhibitors of type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret  Journal Articles
• Evaluation of peroxisome proliferator‐activated receptor agonists on interleukin‐5‐induced eosinophil differentiation  Journal Articles
• Evidence and values: requirements for public reimbursement of drugs for rare diseases--a case study in oncology.  Journal Articles
• IL-8 Increases Transmission of HIV Type 1 in Cervical Explant Tissue  Journal Articles
• Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial  Journal Articles
• Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study.  Journal Articles
• Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study  Journal Articles
• Metastatic renal cell cancer treatments: An indirect comparison meta-analysis  Journal Articles
• Optimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review  Journal Articles
• Paraneoplastic Polyarthritis in Hepatocellular Carcinoma Treated With Lenvatinib  Journal Articles
• Phase I Targeted Combination Trial of Sorafenib and Erlotinib in Patients with Advanced Solid Tumors  Journal Articles
• Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors  Journal Articles
• Phase II Trial of Sorafenib in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Nasopharyngeal Carcinoma  Conferences
• Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?  Journal Articles
• Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma  Journal Articles
• Quizartinib for the treatment of acute myeloid leukemia  Journal Articles
• Safety and Efficacy of Sorafenib in Elderly Patients Treated in the North American Advanced Renal Cell Carcinoma Sorafenib Expanded Access Program  Journal Articles
• Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America  Journal Articles
• Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Sorafenib: A Review of Four Phase I Trials in Patients with Advanced Refractory Solid Tumors  Journal Articles
• Second‐line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real‐world eligibility for cabozantinib, regorafenib, and ramucirumab  Journal Articles
• Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review  Journal Articles
• Selective potentiating effect of RS14203 on a serotoninergic pathway in anesthetized rats  Journal Articles
• Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cells  Journal Articles
• Sorafenib and Radiation Therapy for the Treatment of Advanced Hepatocellular Carcinoma  Journal Articles
• Sorafenib in Combination With Gemcitabine in Recurrent Epithelial Ovarian Cancer: A Study of the Princess Margaret Hospital Phase II Consortium  Journal Articles
• Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy  Journal Articles
• Targeted therapy for metastatic renal cell carcinoma  Journal Articles
• The Cost-Effectiveness of Lenvatinib in the Treatment of Advanced or Unresectable Hepatocellular Carcinoma from a Canadian Perspective  Journal Articles